Moderna to start final testing stage of coronavirus vaccine in July

Moderna to start final testing stage of coronavirus vaccine in July
FILE PHOTO: A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, U.S., May 18, 2020. REUTERS/Brian Snyder/File Photo CHICAGO (Reuters) – Moderna Inc (MRNA.O) on Thursday confirmed it plans to start a trial of 30,000 volunteers of its much-anticipated coronavirus vaccine in July as the company enters the... Read More

Japan’s Fujifilm to spend $928 million to double capacity of Danish drug facility

Japan’s Fujifilm to spend $928 million to double capacity of Danish drug facility
FILE PHOTO: Fujifilm’s company logo (top) is seen at its exhibition hall nearby the headquarters of Fujifilm Holdings Corp in Tokyo, Japan June 12, 2017. REUTERS/Kim Kyung-Hoon/File Photo TOKYO (Reuters) – Fujifilm Holdings Corp (4901.T) will spend $928 million to double capacity at a drug manufacturing facility in Denmark, which it has pledged to use in producing COVID-19 treatments, as... Read More

Pfizer to invest up to $500 million in public drug developers

Pfizer to invest up to $500 million in public drug developers
FILE PHOTO: The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S., August 1, 2016. REUTERS/Andrew Kelly/File Photo (Reuters) – Pfizer Inc (PFE.N) said on Tuesday it will invest up to $500 million into publicly traded drug developers to fund their treatment candidates and provide access to the U.S. drugmaker’s scientific expertise. Pfizer said it will... Read More

Moderna rally loses steam over COVID-19 vaccine worries

Moderna rally loses steam over COVID-19 vaccine worries
FILE PHOTO: A sign marks the headquarters of Moderna Therapeutics, which is developing a vaccine against the coronavirus disease (COVID-19), in Cambridge, Massachusetts, U.S., May 18, 2020. REUTERS/Brian Snyder (Reuters) – Shares of biotechs racing to make coronavirus vaccines, including Moderna Inc (MRNA.O), fell about 10% on Wednesday, as investor concerns grew about the prospects of the experimental products that... Read More

S&P 500 rises on economic recovery and vaccine hopes, pulls back from highs

S&P 500 rises on economic recovery and vaccine hopes, pulls back from highs
New York (Reuters) – U.S. stocks closed higher on Tuesday on optimism about the development of coronavirus vaccines and a revival of business activity, but the S&P 500 failed to hold above the key psychological level of 3,000 points. Stocks pared gains late in the session, after Bloomberg News reported the Trump administration was weighing a range of sanctions on... Read More

S&P 500 clears 3,000 barrier on economic recovery and vaccine hopes

S&P 500 clears 3,000 barrier on economic recovery and vaccine hopes
New York (Reuters) – U.S. stocks jumped on Tuesday, propelling the S&P 500 past the key psychological level of 3,000 points as optimism about developing coronavirus vaccines and the revival of business activity helped investors overlook simmering China-U.S. tensions. The benchmark S&P 500 crossed 3,000 for the first time since March 5, but came off session highs after White House... Read More

S&P 500 clears 3,000 barrier on hopes of recovery, vaccine

S&P 500 clears 3,000 barrier on hopes of recovery, vaccine
(Reuters) – αΉ„U.S. stocks jumped and the S&P 500 crossed 3,000 points on Tuesday as optimism about a potential coronavirus vaccine and a revival in business activity helped investors overlook simmering Sino-U.S. tensions. The benchmark index traded above the key psychological level for the first time since March 5, but came off session highs as White House adviser Larry Kudlow... Read More

S&P 500 tops 3,000 on hopes of economic recovery, COVID-19 vaccine

S&P 500 tops 3,000 on hopes of economic recovery, COVID-19 vaccine
(Reuters) – U.S. stocks jumped and the S&P 500 breached 3,000 points on Tuesday as optimism about a potential coronavirus vaccine and a revival in business activity helped investors overlook simmering Sino-U.S. tensions. The benchmark index traded above the key psychological level for the first time since March 5, but came off session highs as White House adviser Larry Kudlow... Read More

S&P 500 tops 3,000 points on hopes of economic recovery, COVID-19 vaccine

S&P 500 tops 3,000 points on hopes of economic recovery, COVID-19 vaccine
(Reuters) – U.S. stocks jumped and the S&P 500 breached 3,000 points on Tuesday as optimism about a potential coronavirus vaccine and a revival in business activity helped investors overlook simmering Sino-U.S. tensions. The benchmark index traded above the key psychological level and also above its 200-day moving average, a closely watched long-term trend indicator, for the first time since... Read More

S&P 500 tops 3,000 pts on hopes of economic recovery, COVID-19 vaccine

S&P 500 tops 3,000 pts on hopes of economic recovery, COVID-19 vaccine
(Reuters) – U.S. stocks jumped and the S&P 500 breached 3,000 points on Tuesday as optimism about a potential coronavirus vaccine and a revival in business activity helped investors overlook simmering Sino-U.S. tensions. Traders wearing masks watch as the Opening Bell rings, on the first day of in-person trading since the closure during the outbreak of the coronavirus disease (COVID-19)... Read More